Data aggregation, also known as meta analysis, is widely used to combine knowledge on parameters shared in common (e.g., average treatment effect) between multiple studies. In this paper, we introduce an attractive data aggregation scheme that pools summary statistics from various existing studies. Our scheme informs the design of new validation studies and yields us unbiased estimators for the shared parameters. In our setup, each existing study applies a LASSO regression to select a parsimonious model from a large set of covariates. It is well known that post-hoc estimators, in the selected model, tend to be biased. We show that a novel technique called \textit{data carving} yields us a new unbiased estimator by aggregating simple summary statistics from all existing studies. Our estimator has two key features: (a) we make the fullest possible use of data, from all studies, without the risk of bias from model selection; (b) we enjoy the added benefit of individual data privacy, because raw data from these studies need not be shared or stored for efficient estimation.
相關內容
Statisticians show growing interest in estimating and analyzing heterogeneity in causal effects in observational studies. However, there usually exists a trade-off between accuracy and interpretability for developing a desirable estimator for treatment effects, especially in the case when there are a large number of features in estimation. To make efforts to address the issue, we propose a score-based framework for estimating the Conditional Average Treatment Effect (CATE) function in this paper. The framework integrates two components: (i) leverage the joint use of propensity and prognostic scores in a matching algorithm to obtain a proxy of the heterogeneous treatment effects for each observation, (ii) utilize non-parametric regression trees to construct an estimator for the CATE function conditioning on the two scores. The method naturally stratifies treatment effects into subgroups over a 2d grid whose axis are the propensity and prognostic scores. We conduct benchmark experiments on multiple simulated data and demonstrate clear advantages of the proposed estimator over state of the art methods. We also evaluate empirical performance in real-life settings, using two observational data from a clinical trial and a complex social survey, and interpret policy implications following the numerical results.
The estimation of unknown parameters in simulations, also known as calibration, is crucial for practical management of epidemics and prediction of pandemic risk. A simple yet widely used approach is to estimate the parameters by minimizing the sum of the squared distances between actual observations and simulation outputs. It is shown in this paper that this method is inefficient, particularly when the epidemic models are developed based on certain simplifications of reality, also known as imperfect models which are commonly used in practice. To address this issue, a new estimator is introduced that is asymptotically consistent, has a smaller estimation variance than the least squares estimator, and achieves the semiparametric efficiency. Numerical studies are performed to examine the finite sample performance. The proposed method is applied to the analysis of the COVID-19 pandemic for 20 countries based on the SEIR (Susceptible-Exposed-Infectious-Recovered) model with both deterministic and stochastic simulations. The estimation of the parameters, including the basic reproduction number and the average incubation period, reveal the risk of disease outbreaks in each country and provide insights to the design of public health interventions.
The focus of precision medicine is on decision support, often in the form of dynamic treatment regimes (DTRs), which are sequences of decision rules. At each decision point, the decision rules determine the next treatment according to the patient's baseline characteristics, the information on treatments and responses accrued by that point, and the patient's current health status, including symptom severity and other measures. However, DTR estimation with ordinal outcomes is rarely studied, and rarer still in the context of interference - where one patient's treatment may affect another's outcome. In this paper, we introduce the proposed weighted proportional odds model (WPOM): a regression-based, doubly-robust approach to single-stage DTR estimation for ordinal outcomes. This method also accounts for the possibility of interference between individuals sharing a household through the use of covariate balancing weights derived from joint propensity scores. Examining different types of balancing weights, we verify the double robustness of WPOM with our adjusted weights via simulation studies. We further extend WPOM to multi-stage DTR estimation with household interference. Lastly, we demonstrate our proposed methodology in the analysis of longitudinal survey data from the Population Assessment of Tobacco and Health study, which motivates this work.
Latent variable models are powerful tools for modeling complex phenomena involving in particular partially observed data, unobserved variables or underlying complex unknown structures. Inference is often difficult due to the latent structure of the model. To deal with parameter estimation in the presence of latent variables, well-known efficient methods exist, such as gradient-based and EM-type algorithms, but with practical and theoretical limitations. In this paper, we propose as an alternative for parameter estimation an efficient preconditioned stochastic gradient algorithm. Our method includes a preconditioning step based on a positive definite Fisher information matrix estimate. We prove convergence results for the proposed algorithm under mild assumptions for very general latent variables models. We illustrate through relevant simulations the performance of the proposed methodology in a nonlinear mixed effects model and in a stochastic block model.
Value at Risk (VaR) and Conditional Value at Risk (CVaR) have become the most popular measures of market risk in Financial and Insurance fields. However, the estimation of both risk measures is challenging, because it requires the knowledge of the tail of the distribution. Therefore, tools from Extreme Value Theory are usually employed, considering that the tail data follow a Generalized Pareto distribution (GPD). Using the existing relations from the parameters of the baseline distribution and the limit GPD's parameters, we define highly informative priors that incorporate all the information available for the whole set of observations. We show how to perform Metropolis-Hastings (MH) algorithm to estimate VaR and CVaR employing the highly informative priors, in the case of exponential, stable and Gamma distributions. Afterwards, we perform a thorough simulation study to compare the accuracy and precision provided by three different methods. Finally, data from a real example is analyzed to show the practical application of the methods.
Treatment effect estimation is of high-importance for both researchers and practitioners across many scientific and industrial domains. The abundance of observational data makes them increasingly used by researchers for the estimation of causal effects. However, these data suffer from biases, from several weaknesses, leading to inaccurate causal effect estimations, if not handled properly. Therefore, several machine learning techniques have been proposed, most of them focusing on leveraging the predictive power of neural network models to attain more precise estimation of causal effects. In this work, we propose a new methodology, named Nearest Neighboring Information for Causal Inference (NNCI), for integrating valuable nearest neighboring information on neural network-based models for estimating treatment effects. The proposed NNCI methodology is applied to some of the most well established neural network-based models for treatment effect estimation with the use of observational data. Numerical experiments and analysis provide empirical and statistical evidence that the integration of NNCI with state-of-the-art neural network models leads to considerably improved treatment effect estimations on a variety of well-known challenging benchmarks.
We propose a robust and reliable evaluation metric for generative models by introducing topological and statistical treatments for rigorous support estimation. Existing metrics, such as Inception Score (IS), Frechet Inception Distance (FID), and the variants of Precision and Recall (P&R), heavily rely on supports that are estimated from sample features. However, the reliability of their estimation has not been seriously discussed (and overlooked) even though the quality of the evaluation entirely depends on it. In this paper, we propose Topological Precision and Recall (TopP&R, pronounced 'topper'), which provides a systematic approach to estimating supports, retaining only topologically and statistically important features with a certain level of confidence. This not only makes TopP&R strong for noisy features, but also provides statistical consistency. Our theoretical and experimental results show that TopP&R is robust to outliers and non-independent and identically distributed (Non-IID) perturbations, while accurately capturing the true trend of change in samples. To the best of our knowledge, this is the first evaluation metric focused on the robust estimation of the support and provides its statistical consistency under noise.
Qini curves have emerged as an attractive and popular approach for evaluating the benefit of data-driven targeting rules for treatment allocation. We propose a generalization of the Qini curve to multiple costly treatment arms, that quantifies the value of optimally selecting among both units and treatment arms at different budget levels. We develop an efficient algorithm for computing these curves and propose bootstrap-based confidence intervals that are exact in large samples for any point on the curve. These confidence intervals can be used to conduct hypothesis tests comparing the value of treatment targeting using an optimal combination of arms with using just a subset of arms, or with a non-targeting assignment rule ignoring covariates, at different budget levels. We demonstrate the statistical performance in a simulation experiment and an application to treatment targeting for election turnout.
Meta-analysis aggregates information across related studies to provide more reliable statistical inference and has been a vital tool for assessing the safety and efficacy of many high profile pharmaceutical products. A key challenge in conducting a meta-analysis is that the number of related studies is typically small. Applying classical methods that are asymptotic in the number of studies can compromise the validity of inference, particularly when heterogeneity across studies is present. Moreover, serious adverse events are often rare and can result in one or more studies with no events in at least one study arm. While it is common to use arbitrary continuity corrections or remove zero-event studies to stabilize or define effect estimates in such settings, these practices can invalidate subsequent inference. To address these significant practical issues, we introduce an exact inference method for comparing event rates in two treatment arms under a random effects framework, which we coin "XRRmeta". In contrast to existing methods, the coverage of the confidence interval from XRRmeta is guaranteed to be at or above the nominal level (up to Monte Carlo error) when the event rates, number of studies, and/or the within-study sample sizes are small. XRRmeta is also justified in its treatment of zero-event studies through a conditional inference argument. Importantly, our extensive numerical studies indicate that XRRmeta does not yield overly conservative inference. We apply our proposed method to reanalyze the occurrence of major adverse cardiovascular events among type II diabetics treated with rosiglitazone and in a more recent example examining the utility of face masks in preventing person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19).
The quantile varying coefficient (VC) model can flexibly capture dynamical patterns of regression coefficients. In addition, due to the quantile check loss function, it is robust against outliers and heavy-tailed distributions of the response variable, and can provide a more comprehensive picture of modeling via exploring the conditional quantiles of the response variable. Although extensive studies have been conducted to examine variable selection for the high-dimensional quantile varying coefficient models, the Bayesian analysis has been rarely developed. The Bayesian regularized quantile varying coefficient model has been proposed to incorporate robustness against data heterogeneity while accommodating the non-linear interactions between the effect modifier and predictors. Selecting important varying coefficients can be achieved through Bayesian variable selection. Incorporating the multivariate spike-and-slab priors further improves performance by inducing exact sparsity. The Gibbs sampler has been derived to conduct efficient posterior inference of the sparse Bayesian quantile VC model through Markov chain Monte Carlo (MCMC). The merit of the proposed model in selection and estimation accuracy over the alternatives has been systematically investigated in simulation under specific quantile levels and multiple heavy-tailed model errors. In the case study, the proposed model leads to identification of biologically sensible markers in a non-linear gene-environment interaction study using the NHS data.
小貼士
登錄享
注冊地址： 北京市海淀區羊坊店路18號2幢3層301-191